JAMA

Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension

Retrieved on: 
Wednesday, November 8, 2023
JAMA, FDA, Harvard Medical School, Brigham and Women's Hospital, Food, American Medical Association, Blood pressure, Physician, Mortality, MD, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Journal, Hypertension, Division, Treatments for overactive bladder, Diabetes, RDN, Patient, Hospital, Associate, Pharmaceutical industry, ReCore, Endocrinology, Medicine

PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.

Key Points: 
  • Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.
    PALO ALTO, Calif., Nov. 8, 2023 /PRNewswire/ -- Recor Medical, Inc. ("Recor") and its parent company, Otsuka Medical Devices Co., Ltd. ("Otsuka Medical Devices") today announced the U.S. Food and Drug Administration (FDA) has approved Recor's Paradise™ Ultrasound Renal Denervation (RDN) system for the treatment of hypertension.
  • The Paradise system is intended as an adjunctive treatment option when lifestyle changes and medications have not adequately controlled a patient's blood pressure.
  • The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.
  • Recor has been focused on developing and testing the Paradise Ultrasound RDN system for the treatment of hypertension since 2009.

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
JAMA, Nissen, Insurance, BP, Obesity, Biotechnology, American Medical Association, Blood pressure, Treatment, American Heart Association, Uncontrolled, Albuminuria, Conference, Journal, R, Poster, Society, Chronic kidney disease, Cleveland, ASN, Hypertension, Research and development, Medicare Part D, CKD, Safety, AHA, Therapy, Patient, Investment, Cleveland Clinic, Administration, Conference call, Pharmaceutical industry, Cryptocurrency, Part

RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.

Key Points: 
  • ET –
    RADNOR, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced financial results for the quarter ending September 30, 2023, and provided a corporate update.
  • Research and Development (R&D) expenses were $22.5 million for the quarter ended September 30, 2023, compared to $6.1 million for the quarter ended September 30, 2022.
  • General and Administrative (G&A) expenses were $3.8 million for the quarter ended September 30, 2023, compared to $1.4 million for the quarter ended September 30, 2022.
  • Net loss was $22.8 million for the quarter ended September 30, 2023, compared to $6.7 million for the quarter ended September 30, 2022.

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Retrieved on: 
Thursday, November 2, 2023
JAMA, Mercury (element), BP, BMI, Obesity, Physician, Blood pressure, Target, American Medical Association, Publication, American Heart Association, Journal, Society, American Society of Nephrology, Chronic kidney disease, Hypertension, ASN, Risk, Factorization of polynomials, Body mass index, CKD, AHA, Therapy, Mercury, Pharmaceutical industry

RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2–5.

Key Points: 
  • The data were presented during the Late-Breaking Posters session at the American Society of Nephrology (ASN) Kidney Week 2023, which is being held in Philadelphia from November 2–5.
  • In this new analysis, investigators identified a population of responders to lorundrostat who experienced a median reduction in systolic blood pressure (BP) of 32 millimeters of mercury (mmHg).
  • “We were able to show in this post-hoc analysis additional evidence corroborating the association between BMI and blood pressure reduction with lorundrostat.
  • Target-HTN trial results support the transition to late-stage development of lorundrostat as a treatment for uncontrolled and resistant hypertension.

Ambry Genetics Unveils at ASHG New Insights on the Use of Multiomic Testing in 43,000 Patient Study

Retrieved on: 
Saturday, November 4, 2023
Science, Biotechnology, Research, Oncology, General Health, Health, Genetics, Clinical Trials, ASHG, Patient, Cancer, VUS, Genetic testing, Ambiguity, Health equity, RNA, JAMA, Society, Genome, Database, Disease, Classification, American Society of Human Genetics, Medicine, Biology, Human genetics, JAMA Oncology, DNA, Vaccine, Pharmaceutical industry

Key findings from this study indicate that RNA-dependent classifications were instrumental in enhancing the accuracy of genetic testing.

Key Points: 
  • Key findings from this study indicate that RNA-dependent classifications were instrumental in enhancing the accuracy of genetic testing.
  • Reducing Inconclusive Rates: The number of variants of uncertain significance reduced considerably, providing clarity and enhancing the overall reliability of multi-gene panel testing.
  • Patients and the healthcare teams who care for them deserve nothing less,” said CEO of Ambry Genetics, Tom Schoenherr.
  • It is a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India

Retrieved on: 
Friday, October 27, 2023
JAMA, Name, FDA, Trastuzumab, SCLC, Policy, Stomach, Food, European Commission, Cancer, ESCC, Intas Pharmaceuticals, American Medical Association, Independence, Lung cancer, MSI-H, European Medicines Agency, MSI, EC, Regulation of tobacco by the U.S. Food and Drug Administration, Carcinoma, Research, Commonwealth, Journal, Senior, Civil service commission, Growth, Clinical trial, Partnership, EMA, ASEAN, Patient, Nature Medicine, Fosun Pharma, Pharmaceutical industry, Accord

In 2021, Henlius granted Intas the exclusive rights to develop and commercialize HLX02 in the United States (U.S.) and Canada.

Key Points: 
  • In 2021, Henlius granted Intas the exclusive rights to develop and commercialize HLX02 in the United States (U.S.) and Canada.
  • Ping Cao, Senior Vice President and Chief Business Development Officer of Henlius, said, "Henlius and Intas first entered into a collaboration in 2018.
  • Binish Chudgar, Vice-Chairman & Managing Director, Intas Pharmaceuticals Ltd., said, "We are excited to reinforce our long-standing partnership with Henlius.
  • This collaboration will further bolster Intas' global oncology portfolio, underlining our commitment to delivering innovative healthcare solutions worldwide.

Fujitsu showcase at Japan Mobility Show 2023 highlights solutions that contribute to sustainability and wellbeing

Retrieved on: 
Thursday, October 19, 2023
Koto, Tokyo Motor Show, Tokyo Big Sight, Behavior, Show, DE, Sun, Corporation, JAMA, Social, Sign language, Disaster, Corporate title, Mobility, SEVP, Travel, Address, Noise, Diversity, Hearing, Television, Fujitsu

TOKYO, Oct 19, 2023 - (JCN Newswire) - Fujitsu today announced that it will exhibit at the Japan Mobility Show 2023, which will be held at Tokyo Big Sight in Japan from Thursday, October 26, to Sunday, November 5, 2023.

Key Points: 
  • TOKYO, Oct 19, 2023 - (JCN Newswire) - Fujitsu today announced that it will exhibit at the Japan Mobility Show 2023, which will be held at Tokyo Big Sight in Japan from Thursday, October 26, to Sunday, November 5, 2023.
  • Fujitsu's display is a part of the Tokyo Future Tour, one of the Show's headlining events, which is based on the concept of a future Tokyo that transformed by mobility.
  • The system uses AI to visualize environmental sounds, such as station announcements and the sound of trains running, as text, sign language, and onomatopoeia.
  • Venue: Tokyo Big Sight (Address: 3-11-1, Ariake, Koto-ku, Tokyo, Japan) *Fujitsu will exhibit in the Tokyo Future Tour area of West Halls.

October is ADHD Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
JAMA, FDA, Drug Enforcement Administration, Attention, Education, Food, Child, Policy, American Medical Association, National Disability Employment Awareness Month, Prevalence, US Food Sovereignty Alliance, DEA, Conference, Journal, Drug, Approximation error, Letter, White, Caregiver, COVID-19, Annual International Conference on Real Options, ADDA, Woman, Patient, Diagnosis, Attention deficit hyperactivity disorder controversies, ADHD, ACO, Parent, Mental health, Dietary supplement, Nursing

Each October during ADHD Awareness Month, CHADD joins forces with the ADHD Coaches Organization (ACO) and the Attention Deficit Disorder Association (ADDA) to build a stronger understanding of ADHD, and to provide valuable programming and resources.

Key Points: 
  • Each October during ADHD Awareness Month, CHADD joins forces with the ADHD Coaches Organization (ACO) and the Attention Deficit Disorder Association (ADDA) to build a stronger understanding of ADHD, and to provide valuable programming and resources.
  • The theme for Awareness Month this year is Moving Forward with ADHD in 2023.
  • This ADHD Awareness Month, the experts at CHADD have identified three pressing concerns in need of attention if we are to move forward as a community in enabling individuals with ADHD to lead successful lives.
  • Beyond ADHD Awareness Month, the coalition members―CHADD, ACO and ADDA―will host the 2023 Annual International Conference on ADHD in Baltimore, Maryland, from November 30 to December 2, followed by an online conference option on December 5 and 6.

Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C

Retrieved on: 
Wednesday, October 25, 2023
Science, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Hospitals, Clinical Trials, WHO, Urinary tract infection, Survival, FRCP, Patient, Vitamin C, Simvastatin, Royal Victoria Hospital, Montreal, Bronchopneumonia, MPH, Global Coalition Against Pneumonia, Oregon Health & Science University, University, Respiratory tract infection, JAMA, Professor, Vitamin, Multimedia, Queen's University Belfast, University of Pittsburgh School of Medicine, Learning, Critical Care Medicine (journal), COVID, Clinical trial, Intensive care unit, Hospital, NEJM, Probability, Pittsburgh, European Society of Clinical Microbiology and Infectious Diseases, Wilfrid Sellars, SUNY Downstate Health Sciences University, Hospice and palliative medicine, Intensive care medicine, Royal Victoria Hospital, UPMC, Consultant, Ohio State University Wexner Medical Center, Pharmaceutical industry, Dietary supplement, MD

Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.

Key Points: 
  • Vitamin C is widely available around the world and was used in some settings for the treatment of COVID-19.
  • Through harmonizing two clinical trials – REMAP-CAP and LOVIT-COVID – over 2500 patients in 20 countries took part, including both critically ill and non-critically ill patients with COVID-19 in hospital.
  • It was shown that high dose vitamin C did not improve outcomes for patients.
  • Intravenous Vitamin C for Patients Hospitalized with COVID-19: Two Harmonized Randomized Clinical Trials.

Medical Transcription Market in the US to grow by USD 2.06 billion between 2021 - 2026, Growth Driven by Growing need for automated medical transcripts - Technavio

Retrieved on: 
Monday, October 23, 2023
JAMA, Documentation, Speech, Health care, Information, Key (company), American Medical Association, Physician, Certification, Medical tourism, Journal, Software, Growth, Hospital, POM, ISO 9001:2015, Amazon (company), Patient, ISO, Medical device, Marianne Elisabeth Lloyd-Dolbey

The potential growth difference for the medical transcription market in the US between 2021 and 2026 is USD 2.06 billion.

Key Points: 
  • The potential growth difference for the medical transcription market in the US between 2021 and 2026 is USD 2.06 billion.
  • The market is driven by the growing need for automated medical transcripts.
  • Get deeper insights into the market size, current market scenario, future growth opportunities, major growth driving factors, the latest trends, and much more.
  • Key Companies in the medical transcription market in the US:
    3M Co., Aquity LLC, Athreon, CBAY Transcription Inc., Crimson Interactive Pvt.

New PRA Report: Healthcare Price Transparency Can Reduce Healthcare Costs by More than $1 Trillion Annually

Retrieved on: 
Wednesday, October 18, 2023
Knowledge, Health, Organization for Economic Cooperation, Congress, GDP, OECD, JAMA, Fraud, Patient, Hospital, Public policy, Health care, PRA, Multimedia, Pharmaceutical industry, Health insurance

WASHINGTON, Oct. 18, 2023 /PRNewswire/ -- Today, PatientRightsAdvocate.org (PRA) published a report co-authored by Founder and Chairman Cynthia Fisher and economist Dr. Arthur Laffer that concludes healthcare price transparency can reduce national healthcare spending by more than $1 trillion annually and extend American life expectancy.

Key Points: 
  • "Price transparency provides the opportunity to lower runaway costs and provide access to care with knowledge of quality and outcomes.
  • "Healthcare price transparency can save Americans more than $1 trillion a year on healthcare spending and lengthen lifespans by ushering in a pro-consumer healthcare marketplace that empowers patients to choose affordable care when they need it.
  • If the U.S. could match other top ten OECD nations' 11.9% of GDP spending performance through price transparency reforms, it would cut its annual healthcare spending from $4.1 trillion to $2.8 trillion, saving $1.3 trillion.
  • PatientRightsAdvocate.org (PRA) is a leading national healthcare price transparency organization dedicated to ushering in systemwide transparency through advocacy, testimony, media, legal research, and grassroots campaigns.